How variability in PSA levels affects prostate cancer risk assessment and biopsy decisions
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers
This study is looking at how changes in PSA levels can help doctors make better decisions about prostate cancer risk and whether a biopsy is needed, aiming to make testing more accurate and avoid unnecessary procedures for men with different PSA levels.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10898687 on NIH RePORTER |
What this research studies
This research investigates how fluctuations in prostate-specific antigen (PSA) levels can influence clinical decisions regarding prostate cancer risk stratification and the need for biopsies. By analyzing serial screening samples, the study aims to improve the accuracy of PSA testing and reduce unnecessary procedures. It also explores the role of additional markers, such as microseminoprotein-ß, in enhancing the predictive power of PSA measurements. The goal is to provide a more reliable assessment of prostate cancer risk, particularly for men with varying PSA levels over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are men undergoing PSA testing for prostate cancer screening, particularly those with fluctuating PSA levels.
Not a fit: Patients who have already been diagnosed with prostate cancer or those who are not undergoing PSA testing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate prostate cancer risk assessments, reducing unnecessary biopsies and improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using statistical models to enhance PSA testing specificity, indicating that this approach may lead to significant advancements in prostate cancer detection.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Eastham, James a — Sloan-Kettering Inst Can Research
- Study coordinator: Eastham, James a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.